References
Ratajczak, J. et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat. Commun. 7, 13103 (2016).
Grozio, A. et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat. Metab. 1, 47–57 (2019).
Yoshino, J., Mills, K. F., Yoon, M. J. & Imai, S.Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice.Cell Metab. 14, 528–536 (2011).
Yoshino, J. & Imai, S. Accurate measurement of nicotinamide adenine dinucleotide (NAD+) with high-performance liquid chromatography. Methods Mol. Biol. 1077, 203–215 (2013).
Trammell, S. A. et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat. Commun. 7, 12948 (2016).
Trammell, S. A. & Brenner, C. Targeted, LCMS-based metabolomics for quantitative measurement of NAD+ metabolites. Comput. Struct. Biotechnol. J. 4, e201301012 (2013).
Zhao, Z. Y. et al. A cell-permeant mimetic of NMN activates SARM1 to produce cyclic ADP-ribose and induce non-apoptotic cell death. iScience 15, 452–466 (2019).
Nikiforov, A., Dölle, C., Niere, M. & Ziegler, M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J. Biol. Chem. 286, 21767–21778 (2011).
Grozio, A. et al. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. J. Biol. Chem. 288, 25938–25949 (2013).
Sociali, G. et al. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. Oncotarget 7, 2968–2984 (2016).
Fletcher, R. S. et al. Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells. Mol. Metab. 6, 819–832 (2017).
Vaur, P. et al. Nicotinamide riboside, a form of vitamin B3, protects against excitotoxicity-induced axonal degeneration. FASEB J. 31, 5440–5452 (2017).
Author information
Authors and Affiliations
Contributions
M.S.S. and C.B. analysed the data. C.B. wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
C.B. owns stock in and is chief scientific adviser to ChromaDex, Inc. M.S. declares no competing interests.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Schmidt, M.S., Brenner, C. Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nat Metab 1, 660–661 (2019). https://doi.org/10.1038/s42255-019-0085-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s42255-019-0085-0
- Springer Nature Limited
This article is cited by
-
Absolute quantification of nicotinamide mononucleotide in biological samples by double isotope-mediated liquid chromatography-tandem mass spectrometry (dimeLC-MS/MS)
npj Aging (2024)
-
Targeting NAD Metabolism for the Therapy of Age-Related Neurodegenerative Diseases
Neuroscience Bulletin (2024)
-
Prioritization of genes associated with type 2 diabetes mellitus for functional studies
Nature Reviews Endocrinology (2023)
-
Balancing NAD+ deficits with nicotinamide riboside: therapeutic possibilities and limitations
Cellular and Molecular Life Sciences (2022)
-
Enzymology of extracellular NAD metabolism
Cellular and Molecular Life Sciences (2021)